Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 79,352 shares changed hands during mid-day trading, an increase of 202% from the previous session's volume of 26,280 shares.The stock last traded at $17.04 and had previously closed at $16.96.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on TLX shares. Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th.
Check Out Our Latest Analysis on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Performance
The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The firm has a fifty day moving average of $17.06 and a 200 day moving average of $16.94.
Institutional Trading of Telix Pharmaceuticals
An institutional investor recently bought a new position in Telix Pharmaceuticals stock. ABC Arbitrage SA purchased a new position in shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
